Apr 01, 2022
RNS Number : 9191G MaxCyte, Inc. 01 April 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Total Voting Rights   Gaithersburg, Maryland - 1 April 2022 :       MaxCyte (LSE: MXCT), a leading commercial cell - engineering company focused on providing enabling platform technologies to advance
Mar 28, 2022
RNS Number : 2646G MaxCyte, Inc. 28 March 2022         The following amendments have been made to the Grant of Options and PDMR Dealing announcement released on 28 March 2022 at 07:00 under RNS number 1548G.   An incorrect Identification Code in section 4.b has been removed.
Mar 28, 2022
RNS Number : 1548G MaxCyte, Inc. 28 March 2022       MaxCyte, Inc. (" MaxCyte " or the "Company")   Grant of Options and PDMR Dealing   Gaithersburg, Maryland - 28 March 2022 :   MaxCyte, Inc. (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling
Mar 23, 2022
RNS Number : 6718F MaxCyte, Inc. 23 March 2022         MaxCyte Reports Fourth Quarter and Full Year Financial Results   MaxCyte Provides Initial 2022 Guidance   GAITHERSBURG, MD , March 23, 2022   - MaxCyte, Inc. , (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused
Mar 22, 2022
MaxCyte Provides Initial 2022 Guidance GAITHERSBURG, Md., March 22, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT) is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as
Mar 10, 2022
RNS Number : 2726E MaxCyte, Inc. 10 March 2022     MaxCyte, Inc. Names Cenk Sumen Chief Scientific Officer   Dr . Sumen brings extensive experience in scientific and technology evaluation,  process development and leadership.     GAITHERSBURG, Md.   Mar. 10, 2022 - MaxCyte, Inc.
Mar 09, 2022
Dr. Sumen brings extensive experience in scientific and technology evaluation, process development and leadership. GAITHERSBURG, Md., March 09, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT, MXCN), a leading commercial cell-engineering company focused on providing enabling
Mar 08, 2022
RNS Number : 0701E MaxCyte, Inc. 08 March 2022   TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
Mar 03, 2022
RNS Number : 5270D MaxCyte, Inc. 03 March 2022     TR-1: S tandard form for notification of major holdings   NOTIFICATION OF MAJOR HOLDINGS   (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the underlying issuer of existing
Mar 01, 2022
RNS Number : 1158D MaxCyte, Inc. 01 March 2022     MaxCyte, Inc. (" MaxCyte " or the "Company") Block Listing Return   Gaithersburg, Maryland - 1 March 2022:      MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT), a leading provider of enabling   platform technologies for ex-vivo cell engineering,   makes
Displaying 31 - 40 of 52